UNSPSC 51361703: Valnoctamide

This classification denotes an amide with the molecular formula C8H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O25NRX9YG, chemically known as valeramide, 2-ethyl-3-methyl- but generally known as valnoctamide, which bears US NIH Compound Identifier 20140. European Medicines Agency schedules Valnoctamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00010MIG. World Health Organization schedules valnoctamide in its Anatomical Therapeutic Chemical (ATC) Classification.

VALNOCTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valnoctamide under HS 29241900 and SITC 51471. As of Q4 2014, VALNOCTAMIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(N)C(C(CC)C)CC.

UNSPSC 51361703 Valnoctamide is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent opportunities show state and local governments buying a wider range of pharmaceuticals and pharmacy-related services than the specific code name suggests. Seminole County, Florida, for example, is procuring naloxone and drug deactivation systems through an IFB posted June 30, 2026, with a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is soliciting generic multi-source pharmaceuticals and OTC products through an RFP due March 26, 2026, with awards effective July 1, 2026 and distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. The issuing-body mix includes county health departments, state pharmacy agencies, and cooperative purchasing vehicles serving multiple jurisdictions. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, to explore direct-to-manufacturer prescription programs, signaling state-level interest in reshaping pharmaceutical procurement channels outside traditional pharmacy benefit managers and group purchasing organizations.

Recent activity concentrates in Florida, Minnesota (serving Oregon and other participating states through MMCAP), and Texas, with the cooperative purchasing vehicle and state HHS agencies dominating the solicitation landscape. Seminole County's IFB requires 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; vendors must provide electronic bids, include all shipping costs, maintain specified insurance coverage including commercial general liability and professional liability, and comply with E-Verify and drug-free workplace requirements, with potential FEMA funding introducing additional federal compliance obligations. MMCAP's RFP requires vendors to supply pharmaceuticals through three authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three wholesalers, and pay a 3 percent administrative fee; pricing is weighted at 75 percent of the evaluation, with proposals due March 26, 2026 and a question cutoff of February 18, 2026. The Texas RFI, by contrast, represents exploratory procurement seeking vendor capabilities for direct manufacturer relationships rather than a formal bid cycle.